WO2005049678A2 - Block copolymers of acrylates and methacrylates with fluoroalkenes - Google Patents
Block copolymers of acrylates and methacrylates with fluoroalkenes Download PDFInfo
- Publication number
- WO2005049678A2 WO2005049678A2 PCT/US2004/037474 US2004037474W WO2005049678A2 WO 2005049678 A2 WO2005049678 A2 WO 2005049678A2 US 2004037474 W US2004037474 W US 2004037474W WO 2005049678 A2 WO2005049678 A2 WO 2005049678A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rapamycin
- group
- fluorinated
- implantable device
- block
- Prior art date
Links
- 0 CCC(C(C(C)(C)*(C)CC(*)(*(C)C)C(O*)=O)(F)F)C(C(C(C)(C)*CC(*)(*)C(O*)=O)(C(F)(F)F)F)(F)F Chemical compound CCC(C(C(C)(C)*(C)CC(*)(*(C)C)C(O*)=O)(F)F)C(C(C(C)(C)*CC(*)(*)C(O*)=O)(C(F)(F)F)F)(F)F 0.000 description 5
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L53/00—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D153/00—Coating compositions based on block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Coating compositions based on derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31855—Of addition polymer from unsaturated monomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/31504—Composite [nonstructural laminate]
- Y10T428/31855—Of addition polymer from unsaturated monomers
- Y10T428/31938—Polymer of monoethylenically unsaturated hydrocarbon
Definitions
- This invention generally relates to fluorinated and nonfluorinated block copolymer and composition formed therefrom useful for coating an implantable device such as a drug eluting stent.
- Description of the Background Blood vessel occlusions are commonly treated by mechanically enhancing blood flow in the affected vessels, such as by employing a stent.
- Stents are used not only for mechanical intervention but also as vehicles for providing biological therapy.
- the stent can be coated with a biocompatible polymeric coating.
- the biocompatible polymeric coating can function either as a permeable layer or a carrier to allow a controlled delivery of the agent.
- Fluorinated polymers such as poly(vinylidene fluoride-co-hexafluoropropylene), have been used to form drug-eluting stent (DES) coatings and can effectively control the release of pharmaceutical agents from a stent.
- DES coatings formed of these fluorinated polymers also have excellent mechanical properties and are biocompatible and biologically inert.
- polymers of fluorinated olefins are very hydrophobic and may have low glass transition temperatures. Too high a hydrophobicity of the polymeric coating on a DES often reduces the permeability of the coating and thus slows down the release rate of a drug on the coating to an undesirable level.
- the polymer and methods of making the polymer disclosed herein address the above described problems.
- a fluorinated block copolymer comprising a fluorinated block and a non-fluorinated block.
- the non-fluorinated block of the polymer provides improved vascular responses and/or improved permeability for controlled release of pharmaceutical agents.
- the non-fluorinated block comprises a polyolefinic block of the following structure: wherein Ri is -CH 3 , -CF 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 , -phenyl, naphthyl, -COOR 3 , or -CONRsRi; wherein R 2 is -H, -CH 3 , -CF 3 , -CH 2 CH 3 , -CH 2 CH CH 3 , -CH 2 CH 2 CH 2 CH 3 , -phenyl, or naphthalenyl; and wherein R 3 and Rj are -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 OH, or -PEG.
- the fluorinated block can be, for example, a block of poly(fluor
- the fluorinated block copolymer has a structure of the following:
- Ri is -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 OH, or -PEG; and wherein R 2 is -H, -CH 3 , -CF 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 , -phenyl, or naphthyl;.
- the polymer can form a coating composition for coating an implantable device and/or a coating formed thereof for controlling the release rate of a bioactive agent.
- the block copolymer can be formed by polymerizing a non-fluorinated olefin such as acrylate, methacrylate, or styrene in the presence of a copper catalyst, such as an ATRP (atom transfer radical polymerization) catalyst (see, for example, Matyjaszewski, K. Controlled Radical Polymerization; American Chemical Society: Washington, D.C., 1998; Vol. 685; Honigfort, M. E.; Brittain, W. J.; Bosanac, T.; Wilcox, C. S. Polym. Prepr. 2002, 43, 561), and a fluorinated di-halo macromer.
- ATRP atom transfer radical polymerization
- the fluorinated block copolymer can be used to form a coating composition comprising the fluorinated block copolymer alone or in combination with another material or polymer, optionally with a bioactive agent.
- the coating composition thus formed can be coated onto an implantable device such as a DES.
- the release rate of the bioactive agent on the DES can be controlled by fine-tuning the hydrophobicity of the fluorinated block copolymer using a hydrophilic group such as ethylene glycol or polyethylene glycol.
- Figure 1 is a scheme for making a block copolymer having non-fluorinated blocks bearing a hydrophilic ethylene glycol pendent groups.
- a block copolymer comprising a fluorinated block and a non-fluorinated block and method of making the block copolymer are provided. Also provided herein are a coating on an implantable device comprising the block copolymer and optionally a bioactive agent and method of using the implantable device.
- Fluorinated Block Copolymer A block of non-fluorinated polymer can be incorporated into a fluorinated polyolefm to form a block copolymer comprising a non-fluorinated block and a fluorinated block.
- the non- fluorinated block provides the polymer with improved vascular responses and/or improved permeability which are desirable for controlled release of a bioactive agent.
- the fluorinated block copolymer can be synthesized via a fluorinated macromer where at least one of the two termini of the macromer is functionalized.
- the termini of the fluorinated macromer are functionalized with two halo groups which can be two of chloro, bromo, iodo or a combination thereof.
- the two halo groups can be two iodo groups.
- the functionalized fluorinated macromer can be then be used as a macro-initiator to form a block copolymer with non-fluorinated monomers.
- fluorinated macromer refers to a poly(fluoroolefm).
- the term poly(fluoroolefm) is used inter-exchangeably with the term poly(fluoroalkene).
- the dihalogen fluorinated macromer can be a poly(fluorinated olefin) bearing two halogen groups at both termini.
- This dihalo fluorinated macromer can be readily synthesized by polymerizing a fluorinated olefin or a mixture of a fluorinated olefin in the presence of a dihalide and a peroxide (Ying, et al., Polym. Preprints 39(2):843 (1998); Zhang, et al., Polymer 40:1341 (1999); and Modena, et al, J.
- a diiodo fluorinated macromer having as repeating unit -CF 2 CH 2 CF 2 CF(CF 3 )- can be readily synthesized by polymerizing a mixture of vinylidene fluoride and 1,1,2,3,3,3-hexafluoropropene in the presence of a peroxide and l,2-diiodo-l,l,2,2-tetrafluoroehthane (Scheme 1) (Ying, et al., Polym. Preprints 39(2):843 (1998); Zhang, et al., Polymer 40:1341 (1999); and Modena, et al., J. fluorine Chem. 43 15 (1989)).
- Non-fluorinated Blocks Materials or polymers useful as the non-fluorinated blocks described herein include any polymers or macromers that can be directly attached to a fluorinated macromer described herein or polymers or macromers that can be functionalized to attach one or more functional groups such as hydroxyl, amino, halo, and carboxyl and other linking groups.
- Exemplary materials or polymers useful as the non-fluorinated blocks include, but are not limited to, polyolefins, polyalkylene oxides, polyglycols such as poly(ethylene glycol) and poly(propylene glycol), polylactic acid, poly(lactide-co-glycolide), polyhydroxyalkanoate, poly(hydroxybutyrate-co- valerate); polyorthoester; polyanhydride; poly(glycolic acid-co-trimethylene carbonate); polyphosphoester; polyphosphoester urethane; poly(amino acids); poly(cyanoacrylates); poly(trimethylene carbonate); poly(iminocarbonate); copoly(ether-esters) (e.g., polyolefins, polyalkylene oxides, polyglycols such as poly(ethylene glycol) and poly(propylene glycol), polylactic acid, poly(lactide-co-glycolide), polyhydroxyalkanoate, poly(hydroxybutyrate-co- va
- PEO/PLA polyalkylene oxalates; polyphosphazenes; biomolecules, such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid; polyurethanes; silicones; polyesters; polyolefins; polyisobutylene and ethylene-alphaolefin copolymers; acrylic polymers and copolymers; vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halides, such as polyvinylidene fluoride and polyvinylidene chloride; polyacrylonitrile; polyvinyl ketones; polyvinyl aromatics, such as polystyrene; polyvinyl esters, such as polyvinyl acetate; copolymers of vinyl monomers with each other and olefins, such as ethylene-methyl methacrylate copolymers, acryl
- non-fluorinated block may include fluorinated pendant groups such as -CF 3 .
- the non-fluorinated block can be incorporated into the fluorinated block by polymerizing an unsaturated compound, for example, acrylate or methacrylate using a catalyst such as a copper catalyst in the presence of a di-halo fluorinated macromer.
- a block copolymer with a perfluorinated block can be made from monomers including vinylidene fluoride, hexafluoropropylene, tetrafluoroethylene, and other fluorinated olefins in the presence of a fluorinated dihalide under conditions of a standard radical polymerization (Ying et al., 1998; Zhang et al, 1999; and Modena et al., 1989, supra) to form a fluorinated di-halo macromer which can undergo polymerization with an unsaturated compound via an ATRP catalyst, as shown in Scheme 2 (Perrier, et al., Tetrahedron Lett 58 4053 (2002); Jo, et al., Polym Bull (Berlin) 44:1 (2002)).
- Scheme 2 Perrier, et al., Tetrahedron Lett 58 4053 (2002); Jo, et al., Polym Bull (Berlin) 44:1 (2002)).
- the fluorinated di-halo macromer can be used to attach the macromer to many other types of polymers.
- the di-halo groups can be replaced by many functional groups, for example, functional groups bearing a negative or partially negative charge. This allows the formation of a block copolymer bearing a poly(fluorinated olefin) block and one or two blocks of other nature such as polyesters, polyethers, polyanhydrides, polyglycols, poly(alkylene oxides), polyhydroxyalkanoates, polyphosphazenes, polyurethanes, or other biocompatible polymers commonly used in the art of drug delivery.
- the fluorinated di-halo macromer can form into a metallo macromer, which may be useful for linking the macromer with another biocompatible block or polymer.
- a metallo macromer which may be useful for linking the macromer with another biocompatible block or polymer.
- many different polymers can be made.
- the ratio of the fluorinated block to the non-fluorinated block can be varied, leading to formation of block copolymers having different level of hydrophobicity and permeability with different surface and mechanical properties.
- block copolymers comprising a fluorinated block and non-fluorinated blocks of hydrophilic monomers such as hydroxyethyl methacrylate, hydroxypropyl methacrylate, N-vinyl pyrrolidone, or polyethylene glycol acrylate can be synthesized.
- the monomers with labile hydroxy functionalities can be protected with a protecting group (Pg), which can be cleaved upon completion of the reaction ( Figure 1).
- the protecting group can be, for example, t-butyl-dimethylsilane or trimethylsilane which can then be deprotected in stochiometric yields with acidic hydrolysis.
- the block copolymer described herein has a fluorinated block having the following structure:
- non-fluorinated block has the following structure:
- R can be -CH 3 , -CF 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 , -phenyl, naphthyl, -COOR 3 , or -CONR ⁇ ;
- R 2 can be -H, -CH 3 , -CF 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 , -phenyl, or naphthalenyl; and wherein R 3 and R 4 can be -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 OH, or -PEG.
- the block copolymer has a formula of the following structure: wherein Ri ' can be -CH 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 , -CH 2 CH 2 OH, or - PEG, and wherein R 2 can be -H or -CH 3 , -CF 3 , -CH 2 CH 3 , -CH 2 CH 2 CH 3 , -CH 2 CH 2 CH 2 CH 3 , -phenyl or naphthyl.
- the block copolymer has a formula of the following structure:
- the block copolymer described herein has a fluorinated block having the following structure:
- compositions of Fluorinated Block Copolymers The Fluorinated block copolymer described above can be used to form coating compositions for coating an implantable device, for example, a stent.
- the fluorinated block copolymer can be used alone or in combination with another polymer.
- the composition can include a bioactive agent.
- Bioactive Agents The bioactive agent can be any agent that is biologically active, for example, a therapeutic, prophylactic, or diagnostic agent.
- suitable therapeutic and prophylactic agents include synthetic inorganic and organic compounds, proteins and peptides, polysaccharides and other sugars, lipids, and DNA and RNA nucleic acid sequences having therapeutic, prophylactic or diagnostic activities.
- Nucleic acid sequences include genes, antisense molecules which bind to complementary DNA to inhibit transcription, and ribozymes.
- Compounds with a wide range of molecular weight can be encapsulated, for example, between 100 and 500,000 grams or more per mole.
- suitable materials include proteins such as antibodies, receptor ligands, and enzymes, peptides such as adhesion peptides, saccharides and polysaccharides, synthetic organic or inorganic drugs, and nucleic acids.
- Examples of materials which can be encapsulated include enzymes, blood clotting factors, inhibitors or clot dissolving agents such as streptokinase and tissue plasminogen activator; antigens for immunization; hormones and growth factors; polysaccharides such as heparin; oligonucleotides such as antisense oligonucleotides and ribozymes and retroviral vectors for use in gene therapy.
- Representative diagnostic agents are agents detectable by x-ray, fluorescence, magnetic resonance imaging, radioactivity, ultrasound, computer tomagraphy (CT) and positron emission tomagraphy (PET).
- Ultrasound diagnostic agents are typically a gas such as air, oxygen or perfluorocarbons.
- bioactive agents can be incorporated into a controlled release device. These include hydrophobic, hydrophilic, and high molecular weight macromolecules such as proteins.
- the bioactive compound can be incorporated into polymeric coating in a percent loading of between 0.01% and 70% by weight, more preferably between 1% and 35%% by weight.
- the bioactive agent can be for inhibiting the activity of vascular smooth muscle cells. More specifically, the bioactive agent can be aimed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells for the inhibition of restenosis.
- the bioactive agent can also include any substance capable of exerting a therapeutic or prophylactic effect in the practice of the present invention.
- the bioactive agent can be for enhancing wound healing in a vascular site or improving the structural and elastic properties of the vascular site.
- active agents include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma- Aldrich 1001 West Saint Paul Avenue, Milwaukee, WI 53233; or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin L, actinomycin Xi, and actinomycin .
- the bioactive agent can also fall under the genus of antineoplastic, anti- inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances.
- antineoplastics and/or antimitotics include paclitaxel (e.g. TAXOL ® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g. Taxotere ® , from Aventis S.A., Frankfurt, Germany) methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g.
- Adriamycin ® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin e.g. Mutamycin ® from Bristol-Myers Squibb Co., Stamford, Conn.
- antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein Ilb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as Angiomax a (Biogen, Inc., Cambridge, Mass.).
- cytostatic or antiproliferative agents examples include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten ® and Capozide ® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g.
- calcium channel blockers such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3 -fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor ® from Merck & Co., Inc., Whitehouse Station, NJ), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide.
- PDGF Platelet-Derived Growth Factor
- an antiallergic agent is permirolast potassium.
- Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, tacrolimus, dexamethasone, and rapamycin and structural derivatives or functional analogs thereof, such as 40-O-(2-hydroxy)ethyl-rapamycin (known as Everolimus, available from Novartis as CerticanTM ), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl- rapamycin, and 40-O-tetrazole-rapamycin.
- the foregoing substances are listed by way of example and are not meant to be limiting.
- the dosage or concentration of the bioactive agent required to produce a favorable therapeutic effect should be less than the level at which the bioactive agent produces toxic effects and greater than the level at which non-therapeutic results are obtained.
- the dosage or concentration of the bioactive agent required to inhibit the desired cellular activity of the vascular region can depend upon factors such as the particular circumstances of the patient; the nature of the trauma; the nature of the therapy desired; the time over which the ingredient administered resides at the vascular site; and if other active agents are employed, the nature and type of the substance or combination of substances.
- Therapeutic effective dosages can be determined empirically, for example by infusing vessels from suitable animal model systems and using immunohistochemical, fluorescent or electron microscopy methods to detect the agent and its effects, or by conducting suitable in vitro studies. Standard pharmacological test procedures to determine dosages are understood by one of ordinary skill in the art.
- the coating composition can be coated onto any implantable device by any established coating process, e.g., a spray process.
- the coating process involves dissolving or suspending the composition in a solvent to form a solution or a suspension of the coating composition, and then applying the solution or suspension to an implantable device such as a stent.
- an implantable device may be any suitable medical substrate that can be implanted in a human or veterinary patient.
- a exemplary implantable device is a stent such as DES. Examples of stents include self-expandable stents, balloon-expandable stents, and stent- grafts.
- Implantable devices include grafts (e.g., aortic grafts), artificial heart valves, cerebrospinal fluid shunts, pacemaker electrodes, and endocardial leads (e.g., FLNELLNE and ENDOTAK, available from Guidant Corporation, Santa Clara, CA).
- grafts e.g., aortic grafts
- artificial heart valves e.g., aortic grafts
- cerebrospinal fluid shunts e.g., pacemaker electrodes
- endocardial leads e.g., FLNELLNE and ENDOTAK, available from Guidant Corporation, Santa Clara, CA.
- endocardial leads e.g., FLNELLNE and ENDOTAK, available from Guidant Corporation, Santa Clara, CA.
- endocardial leads e.g., FLNELLNE and ENDOTAK, available from Guidant Corporation, Santa Clara, CA.
- the device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), high nitrogen stainless steel, e.g., BIODUR 108, cobalt chrome alloy L-605, "MP35N,” “MP20N,” ELASTLNITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
- ELGILOY cobalt chromium alloy
- 316L stainless steel
- high nitrogen stainless steel e.g., BIODUR 108, cobalt chrome alloy L-605, "MP35N,” “MP20N,” ELASTLNITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
- MP35N and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from Standard Press Steel Co.,
- MP20N consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum.
- Devices made from bioabsorbable or biostable polymers could also be used with the embodiments of the present invention.
- the implantable device described herein can be used to treat any medical condition, for example, a vascular disorder in an animal such as a human.
- Representative medical conditions that can be treated using the implantable device described herein include, but are not limited to, cancer, restenosis, vulnerable plaque, thrombosis or inflammation.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006539794A JP2007514808A (en) | 2003-11-14 | 2004-11-10 | Block copolymers of acrylates and methacrylates with fluoroalkenes |
EP04800949.2A EP1682593B1 (en) | 2003-11-14 | 2004-11-10 | Block copolymers of acrylates and methacrylates with fluoroalkenes |
ES04800949T ES2420132T3 (en) | 2003-11-14 | 2004-11-10 | Block copolymers of acrylates and methacrylates with fluoroalkenes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/714,111 | 2003-11-14 | ||
US10/714,111 US7261946B2 (en) | 2003-11-14 | 2003-11-14 | Block copolymers of acrylates and methacrylates with fluoroalkenes |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005049678A2 true WO2005049678A2 (en) | 2005-06-02 |
WO2005049678A3 WO2005049678A3 (en) | 2005-09-01 |
Family
ID=34573895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/037474 WO2005049678A2 (en) | 2003-11-14 | 2004-11-10 | Block copolymers of acrylates and methacrylates with fluoroalkenes |
Country Status (6)
Country | Link |
---|---|
US (4) | US7261946B2 (en) |
EP (3) | EP2915829B1 (en) |
JP (1) | JP2007514808A (en) |
ES (2) | ES2420132T3 (en) |
HK (2) | HK1186199A1 (en) |
WO (1) | WO2005049678A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006026521A1 (en) * | 2004-08-31 | 2006-03-09 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrophilic monomers |
US8475844B2 (en) | 2008-04-16 | 2013-07-02 | Boston Scientific Scimed, Inc. | Fluoropolymer-based medical implant coating compositions |
US8932694B2 (en) | 2010-06-29 | 2015-01-13 | Surmodics, Inc. | Fluorinated polymers and lubricious coatings |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US7261946B2 (en) | 2003-11-14 | 2007-08-28 | Advanced Cardiovascular Systems, Inc. | Block copolymers of acrylates and methacrylates with fluoroalkenes |
US9114198B2 (en) * | 2003-11-19 | 2015-08-25 | Advanced Cardiovascular Systems, Inc. | Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same |
US20050208093A1 (en) | 2004-03-22 | 2005-09-22 | Thierry Glauser | Phosphoryl choline coating compositions |
US8980300B2 (en) | 2004-08-05 | 2015-03-17 | Advanced Cardiovascular Systems, Inc. | Plasticizers for coating compositions |
US7604818B2 (en) * | 2004-12-22 | 2009-10-20 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrocarbon monomers |
EP1940484A1 (en) * | 2005-08-25 | 2008-07-09 | Medtronic Vascular, Inc. | Controlled radical polymerization-derived block copolymer compositions for medical device coatings |
US8034874B2 (en) * | 2005-11-23 | 2011-10-11 | Boston Scientific Scimed, Inc. | Medical devices having polymeric regions that contain fluorocarbon-containing block copolymers |
US7867547B2 (en) * | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US20080008736A1 (en) * | 2006-07-06 | 2008-01-10 | Thierry Glauser | Random copolymers of methacrylates and acrylates |
US8685430B1 (en) | 2006-07-14 | 2014-04-01 | Abbott Cardiovascular Systems Inc. | Tailored aliphatic polyesters for stent coatings |
US7794495B2 (en) * | 2006-07-17 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Controlled degradation of stents |
US8293318B1 (en) | 2006-08-29 | 2012-10-23 | Abbott Cardiovascular Systems Inc. | Methods for modulating the release rate of a drug-coated stent |
GB0624729D0 (en) * | 2006-12-12 | 2007-01-17 | Univ Leeds | Reversible micelles and applications for their use |
US10155881B2 (en) * | 2007-05-30 | 2018-12-18 | Abbott Cardiovascular Systems Inc. | Substituted polycaprolactone for coating |
US9737638B2 (en) | 2007-06-20 | 2017-08-22 | Abbott Cardiovascular Systems, Inc. | Polyester amide copolymers having free carboxylic acid pendant groups |
US20090004243A1 (en) | 2007-06-29 | 2009-01-01 | Pacetti Stephen D | Biodegradable triblock copolymers for implantable devices |
US9814553B1 (en) | 2007-10-10 | 2017-11-14 | Abbott Cardiovascular Systems Inc. | Bioabsorbable semi-crystalline polymer for controlling release of drug from a coating |
US20090104241A1 (en) * | 2007-10-23 | 2009-04-23 | Pacetti Stephen D | Random amorphous terpolymer containing lactide and glycolide |
US20090306120A1 (en) * | 2007-10-23 | 2009-12-10 | Florencia Lim | Terpolymers containing lactide and glycolide |
US8642062B2 (en) | 2007-10-31 | 2014-02-04 | Abbott Cardiovascular Systems Inc. | Implantable device having a slow dissolving polymer |
US8216600B2 (en) * | 2007-11-14 | 2012-07-10 | Cordis Corporation | Polymeric materials for medical devices |
EP2231207A1 (en) * | 2007-12-27 | 2010-09-29 | Bausch & Lomb Incorporated | Coating solutions comprising segmented interactive block copolymers |
US20090171049A1 (en) * | 2007-12-27 | 2009-07-02 | Linhardt Jeffrey G | Segmented reactive block copolymers |
US8128983B2 (en) * | 2008-04-11 | 2012-03-06 | Abbott Cardiovascular Systems Inc. | Coating comprising poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network |
US8916188B2 (en) * | 2008-04-18 | 2014-12-23 | Abbott Cardiovascular Systems Inc. | Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block |
US20090285873A1 (en) * | 2008-04-18 | 2009-11-19 | Abbott Cardiovascular Systems Inc. | Implantable medical devices and coatings therefor comprising block copolymers of poly(ethylene glycol) and a poly(lactide-glycolide) |
US20090297584A1 (en) * | 2008-04-18 | 2009-12-03 | Florencia Lim | Biosoluble coating with linear over time mass loss |
US8697113B2 (en) * | 2008-05-21 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Coating comprising a terpolymer comprising caprolactone and glycolide |
US8562669B2 (en) * | 2008-06-26 | 2013-10-22 | Abbott Cardiovascular Systems Inc. | Methods of application of coatings composed of hydrophobic, high glass transition polymers with tunable drug release rates |
US8092822B2 (en) * | 2008-09-29 | 2012-01-10 | Abbott Cardiovascular Systems Inc. | Coatings including dexamethasone derivatives and analogs and olimus drugs |
US8697110B2 (en) * | 2009-05-14 | 2014-04-15 | Abbott Cardiovascular Systems Inc. | Polymers comprising amorphous terpolymers and semicrystalline blocks |
DE102011110909A1 (en) * | 2011-08-18 | 2013-02-21 | Paul Hartmann Ag | Compositions having a skin barrier enhancing drug combination |
WO2016149238A1 (en) * | 2015-03-16 | 2016-09-22 | Arkema Inc. | Modified fluoropolymers |
WO2018038132A1 (en) * | 2016-08-23 | 2018-03-01 | 国立大学法人お茶の水女子大学 | Fluorine-containing polymer |
CN108148204B (en) * | 2017-12-21 | 2020-10-20 | 广东永诺医疗科技有限公司 | Perfluoropolyether-polyethylene glycol block copolymer, preparation method and application thereof |
CN116271249A (en) * | 2023-03-28 | 2023-06-23 | 青岛科技大学 | Fluorine oil filled poly (4-hydroxybutyrate) composite fiber membrane patch, preparation method thereof and anti-adhesion membrane |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US858746A (en) * | 1906-12-03 | 1907-07-02 | Miner Co W H | Draft-rigging for railway-cars. |
JPS584728B2 (en) * | 1976-06-30 | 1983-01-27 | ダイキン工業株式会社 | Method for producing fluorine-containing multi-segmented polymer |
JPS5940066Y2 (en) | 1979-02-13 | 1984-11-12 | 武雄 真城 | Opening device for variable safe ball socket |
JPS5650930A (en) * | 1979-10-02 | 1981-05-08 | Asahi Glass Co Ltd | Rubber stopper for sealing |
JPS6041950B2 (en) * | 1981-09-04 | 1985-09-19 | 旭硝子株式会社 | anticoagulant material |
JPS5920310A (en) * | 1982-07-27 | 1984-02-02 | Daikin Ind Ltd | Easily curable fluorocarbon polymer and composition for its curing |
JPS5940066A (en) * | 1982-08-31 | 1984-03-05 | Daikin Ind Ltd | Sealing material having resistance to lubricating oil |
LU86084A1 (en) * | 1985-09-20 | 1987-04-02 | Faco Sa | ELECTRIC MASSAGE APPARATUS |
US4733665C2 (en) * | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
US4800882A (en) * | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
JPS63249152A (en) * | 1987-04-06 | 1988-10-17 | Canon Inc | Electrophotographic sensitive body |
US6387379B1 (en) * | 1987-04-10 | 2002-05-14 | University Of Florida | Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like |
JPH01103666A (en) * | 1987-05-13 | 1989-04-20 | Mitsubishi Petrochem Co Ltd | Modification of surface property of polymeric material |
US4886062A (en) * | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
US5019096A (en) * | 1988-02-11 | 1991-05-28 | Trustees Of Columbia University In The City Of New York | Infection-resistant compositions, medical devices and surfaces and methods for preparing and using same |
US4931287A (en) * | 1988-06-14 | 1990-06-05 | University Of Utah | Heterogeneous interpenetrating polymer networks for the controlled release of drugs |
US5328471A (en) * | 1990-02-26 | 1994-07-12 | Endoluminal Therapeutics, Inc. | Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens |
US4977901A (en) * | 1988-11-23 | 1990-12-18 | Minnesota Mining And Manufacturing Company | Article having non-crosslinked crystallized polymer coatings |
US5350878A (en) * | 1989-07-26 | 1994-09-27 | Dow Corning Corporation | Fluorinated compounds containing hetero atoms and polymers thereof |
US5971954A (en) * | 1990-01-10 | 1999-10-26 | Rochester Medical Corporation | Method of making catheter |
US6060451A (en) * | 1990-06-15 | 2000-05-09 | The National Research Council Of Canada | Thrombin inhibitors based on the amino acid sequence of hirudin |
US5112457A (en) * | 1990-07-23 | 1992-05-12 | Case Western Reserve University | Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants |
US5455040A (en) * | 1990-07-26 | 1995-10-03 | Case Western Reserve University | Anticoagulant plasma polymer-modified substrate |
US6248129B1 (en) | 1990-09-14 | 2001-06-19 | Quanam Medical Corporation | Expandable polymeric stent with memory and delivery apparatus and method |
US5163952A (en) * | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US5258020A (en) * | 1990-09-14 | 1993-11-02 | Michael Froix | Method of using expandable polymeric stent with memory |
JPH0826087B2 (en) * | 1990-11-29 | 1996-03-13 | ダイキン工業株式会社 | Novel polymer production method |
US5219662A (en) * | 1991-05-23 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Biocompatible polyurethanes by treatment with polyoxazoline block copolymers |
US5573934A (en) | 1992-04-20 | 1996-11-12 | Board Of Regents, The University Of Texas System | Gels for encapsulation of biological materials |
US5464650A (en) * | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
JPH0767895A (en) * | 1993-06-25 | 1995-03-14 | Sumitomo Electric Ind Ltd | Antimicrobial artificial blood vessel and suture yarn for antimicrobial operation |
US5716981A (en) * | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
EG20321A (en) | 1993-07-21 | 1998-10-31 | Otsuka Pharma Co Ltd | Medical material and process for producing the same |
US5723004A (en) * | 1993-10-21 | 1998-03-03 | Corvita Corporation | Expandable supportive endoluminal grafts |
WO1995019796A1 (en) * | 1994-01-21 | 1995-07-27 | Brown University Research Foundation | Biocompatible implants |
AU710504B2 (en) | 1994-03-15 | 1999-09-23 | Brown University Research Foundation | Polymeric gene delivery system |
IT1269513B (en) * | 1994-05-18 | 1997-04-01 | Ausimont Spa | FLUORINATED THERMOPLASTIC ELASTOMERS EQUIPPED WITH IMPROVED MECHANICAL AND ELASTIC PROPERTIES, AND THE RELATED PREPARATION PROCESS |
US5670558A (en) * | 1994-07-07 | 1997-09-23 | Terumo Kabushiki Kaisha | Medical instruments that exhibit surface lubricity when wetted |
US5578073A (en) * | 1994-09-16 | 1996-11-26 | Ramot Of Tel Aviv University | Thromboresistant surface treatment for biomaterials |
AU700903B2 (en) * | 1994-10-12 | 1999-01-14 | Focal, Inc. | Targeted delivery via biodegradable polymers |
US5637113A (en) * | 1994-12-13 | 1997-06-10 | Advanced Cardiovascular Systems, Inc. | Polymer film for wrapping a stent structure |
US5919570A (en) * | 1995-02-01 | 1999-07-06 | Schneider Inc. | Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices |
US6017577A (en) * | 1995-02-01 | 2000-01-25 | Schneider (Usa) Inc. | Slippery, tenaciously adhering hydrophilic polyurethane hydrogel coatings, coated polymer substrate materials, and coated medical devices |
US5605696A (en) * | 1995-03-30 | 1997-02-25 | Advanced Cardiovascular Systems, Inc. | Drug loaded polymeric material and method of manufacture |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6120536A (en) * | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6086921A (en) * | 1995-04-25 | 2000-07-11 | Wintrop-University Hospital | Metal/thiol biocides |
US5674242A (en) * | 1995-06-06 | 1997-10-07 | Quanam Medical Corporation | Endoprosthetic device with therapeutic compound |
US5820917A (en) * | 1995-06-07 | 1998-10-13 | Medtronic, Inc. | Blood-contacting medical device and method |
US7550005B2 (en) | 1995-06-07 | 2009-06-23 | Cook Incorporated | Coated implantable medical device |
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
US6129761A (en) * | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
CA2178541C (en) * | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
US6774278B1 (en) * | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US5667767A (en) * | 1995-07-27 | 1997-09-16 | Micro Therapeutics, Inc. | Compositions for use in embolizing blood vessels |
US5723219A (en) * | 1995-12-19 | 1998-03-03 | Talison Research | Plasma deposited film networks |
US5807937A (en) * | 1995-11-15 | 1998-09-15 | Carnegie Mellon University | Processes based on atom (or group) transfer radical polymerization and novel (co) polymers having useful structures and properties |
ATE330644T1 (en) * | 1995-12-18 | 2006-07-15 | Angiotech Biomaterials Corp | CROSS-LINKED POLYMER MATERIALS AND METHODS FOR USE THEREOF |
US5932299A (en) * | 1996-04-23 | 1999-08-03 | Katoot; Mohammad W. | Method for modifying the surface of an object |
US5994486A (en) * | 1996-05-31 | 1999-11-30 | Wako Pure Chemical Industries, Ltd. | Fluorine-containing macroazo compound |
US5830178A (en) * | 1996-10-11 | 1998-11-03 | Micro Therapeutics, Inc. | Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide |
AU4090997A (en) | 1996-08-30 | 1998-03-19 | Helix Medical Corporation | Medical devices having microbial resistant material properties |
US6530951B1 (en) * | 1996-10-24 | 2003-03-11 | Cook Incorporated | Silver implantable medical device |
US5980972A (en) * | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US5997517A (en) * | 1997-01-27 | 1999-12-07 | Sts Biopolymers, Inc. | Bonding layers for medical device surface coatings |
US5879697A (en) * | 1997-04-30 | 1999-03-09 | Schneider Usa Inc | Drug-releasing coatings for medical devices |
JPH10324788A (en) * | 1997-05-26 | 1998-12-08 | Daikin Ind Ltd | Fluorine-containing elastomer composition |
US6245760B1 (en) * | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6180632B1 (en) * | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6159978A (en) * | 1997-05-28 | 2000-12-12 | Aventis Pharmaceuticals Product, Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6056993A (en) * | 1997-05-30 | 2000-05-02 | Schneider (Usa) Inc. | Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel |
IT1292391B1 (en) * | 1997-06-20 | 1999-02-08 | Ausimont Spa | THERMOPLASTIC ELASTOMERS |
US6110483A (en) * | 1997-06-23 | 2000-08-29 | Sts Biopolymers, Inc. | Adherent, flexible hydrogel and medicated coatings |
US5980928A (en) * | 1997-07-29 | 1999-11-09 | Terry; Paul B. | Implant for preventing conjunctivitis in cattle |
US6121027A (en) * | 1997-08-15 | 2000-09-19 | Surmodics, Inc. | Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups |
US6015541A (en) * | 1997-11-03 | 2000-01-18 | Micro Therapeutics, Inc. | Radioactive embolizing compositions |
IT1296968B1 (en) * | 1997-12-15 | 1999-08-03 | Ausimont Spa | FLUORINATED THERMOPLASTIC ELASTOMERS |
US6110188A (en) * | 1998-03-09 | 2000-08-29 | Corvascular, Inc. | Anastomosis method |
US6258371B1 (en) | 1998-04-03 | 2001-07-10 | Medtronic Inc | Method for making biocompatible medical article |
US20030040790A1 (en) * | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
US7658727B1 (en) | 1998-04-20 | 2010-02-09 | Medtronic, Inc | Implantable medical device with enhanced biocompatibility and biostability |
ES2179646T3 (en) | 1998-04-27 | 2003-01-16 | Surmodics Inc | COATING THAT RELEASES A BIOACTIVE AGENT. |
US20020188037A1 (en) | 1999-04-15 | 2002-12-12 | Chudzik Stephen J. | Method and system for providing bioactive agent release coating |
US6113629A (en) * | 1998-05-01 | 2000-09-05 | Micrus Corporation | Hydrogel for the therapeutic treatment of aneurysms |
US6153252A (en) * | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
AU771367B2 (en) * | 1998-08-20 | 2004-03-18 | Cook Medical Technologies Llc | Coated implantable medical device |
CA2338788A1 (en) | 1998-09-02 | 2000-03-09 | Scimed Life Systems, Inc. | Drug delivery device for stent |
US7662409B2 (en) * | 1998-09-25 | 2010-02-16 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
US6530950B1 (en) * | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
US6143354A (en) * | 1999-02-08 | 2000-11-07 | Medtronic Inc. | One-step method for attachment of biomolecules to substrate surfaces |
WO2000059963A1 (en) * | 1999-03-31 | 2000-10-12 | Universiteit Gent | Fluorinated copolymers for coating biomedical devices and a process for their manufacture |
EP1175236A1 (en) | 1999-04-23 | 2002-01-30 | Agion Technologies, L.L.C. | Stent having antimicrobial agent |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US6177523B1 (en) * | 1999-07-14 | 2001-01-23 | Cardiotech International, Inc. | Functionalized polyurethanes |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6613432B2 (en) | 1999-12-22 | 2003-09-02 | Biosurface Engineering Technologies, Inc. | Plasma-deposited coatings, devices and methods |
US20010007083A1 (en) | 1999-12-29 | 2001-07-05 | Roorda Wouter E. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
EP1126537B1 (en) * | 2000-02-15 | 2010-12-15 | Asahi Glass Company Ltd. | Block polymer, process for producing a polymer, and polymer electrolyte fuel cell |
US20020007214A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US20020005206A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Antiproliferative drug and delivery device |
US20020007213A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US20020007215A1 (en) | 2000-05-19 | 2002-01-17 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
JP2004509192A (en) * | 2000-09-11 | 2004-03-25 | マサチューセッツ・インスティチュート・オブ・テクノロジー | Graft copolymers, methods for grafting hydrophilic chains onto hydrophobic polymers, and articles thereof |
US6746773B2 (en) | 2000-09-29 | 2004-06-08 | Ethicon, Inc. | Coatings for medical devices |
US20020051730A1 (en) | 2000-09-29 | 2002-05-02 | Stanko Bodnar | Coated medical devices and sterilization thereof |
US7261735B2 (en) | 2001-05-07 | 2007-08-28 | Cordis Corporation | Local drug delivery devices and methods for maintaining the drug coatings thereon |
US20020111590A1 (en) | 2000-09-29 | 2002-08-15 | Davila Luis A. | Medical devices, drug coatings and methods for maintaining the drug coatings thereon |
US20020082679A1 (en) | 2000-12-22 | 2002-06-27 | Avantec Vascular Corporation | Delivery or therapeutic capable agents |
US7077859B2 (en) | 2000-12-22 | 2006-07-18 | Avantec Vascular Corporation | Apparatus and methods for variably controlled substance delivery from implanted prostheses |
US6663662B2 (en) | 2000-12-28 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Diffusion barrier layer for implantable devices |
JP2004533277A (en) | 2001-02-09 | 2004-11-04 | エンドルミナル セラピューティクス, インコーポレイテッド | Intramural therapy |
AU2002254158A1 (en) * | 2001-03-08 | 2002-09-24 | Volcano Therapeutics, Inc. | Medical devices, compositions and methods for treating vulnerable plaque |
EP1383504A1 (en) | 2001-04-26 | 2004-01-28 | Control Delivery Systems, Inc. | Sustained release drug delivery system containing codrugs |
EP1429689A4 (en) * | 2001-09-24 | 2006-03-08 | Medtronic Ave Inc | Rational drug therapy device and methods |
US7195640B2 (en) * | 2001-09-25 | 2007-03-27 | Cordis Corporation | Coated medical devices for the treatment of vulnerable plaque |
US20030065377A1 (en) | 2001-09-28 | 2003-04-03 | Davila Luis A. | Coated medical devices |
US7005137B1 (en) * | 2002-06-21 | 2006-02-28 | Advanceed Cardiovascular Systems, Inc. | Coating for implantable medical devices |
US7094256B1 (en) | 2002-12-16 | 2006-08-22 | Advanced Cardiovascular Systems, Inc. | Coatings for implantable medical device containing polycationic peptides |
CN100396717C (en) * | 2003-06-11 | 2008-06-25 | 大金工业株式会社 | Fluorine-containing graft or block polymer |
US7261946B2 (en) * | 2003-11-14 | 2007-08-28 | Advanced Cardiovascular Systems, Inc. | Block copolymers of acrylates and methacrylates with fluoroalkenes |
US7604818B2 (en) * | 2004-12-22 | 2009-10-20 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrocarbon monomers |
US20060235416A1 (en) * | 2005-04-15 | 2006-10-19 | Sdgi Holdings, Inc. | Intervertebral connecting elements |
US9352133B2 (en) * | 2005-06-09 | 2016-05-31 | Boston Scientific Scimed, Inc. | Balloon catheters with increased column strength |
US8435279B2 (en) * | 2005-06-14 | 2013-05-07 | Advanced Cardiovascular Systems, Inc. | Delivery system for a device such as a stent |
CN101300298A (en) * | 2005-11-04 | 2008-11-05 | Ls电线有限公司 | Synthesis of mdh-polymer hybrid particles |
-
2003
- 2003-11-14 US US10/714,111 patent/US7261946B2/en active Active
-
2004
- 2004-11-10 JP JP2006539794A patent/JP2007514808A/en active Pending
- 2004-11-10 ES ES04800949T patent/ES2420132T3/en active Active
- 2004-11-10 WO PCT/US2004/037474 patent/WO2005049678A2/en active Application Filing
- 2004-11-10 EP EP15157882.0A patent/EP2915829B1/en not_active Expired - Fee Related
- 2004-11-10 ES ES13160528.9T patent/ES2541326T3/en active Active
- 2004-11-10 EP EP20130160528 patent/EP2607395B1/en not_active Not-in-force
- 2004-11-10 EP EP04800949.2A patent/EP1682593B1/en not_active Not-in-force
-
2006
- 2006-11-21 US US11/603,455 patent/US8883175B2/en not_active Expired - Fee Related
- 2006-11-21 US US11/603,851 patent/US7875073B2/en not_active Expired - Fee Related
-
2013
- 2013-12-10 HK HK13113716.1A patent/HK1186199A1/en not_active IP Right Cessation
-
2014
- 2014-10-03 US US14/505,918 patent/US9446173B2/en not_active Expired - Fee Related
-
2016
- 2016-02-18 HK HK16101822.4A patent/HK1213927A1/en unknown
Non-Patent Citations (1)
Title |
---|
None |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006026521A1 (en) * | 2004-08-31 | 2006-03-09 | Advanced Cardiovascular Systems, Inc. | Polymers of fluorinated monomers and hydrophilic monomers |
US8475844B2 (en) | 2008-04-16 | 2013-07-02 | Boston Scientific Scimed, Inc. | Fluoropolymer-based medical implant coating compositions |
US8932694B2 (en) | 2010-06-29 | 2015-01-13 | Surmodics, Inc. | Fluorinated polymers and lubricious coatings |
Also Published As
Publication number | Publication date |
---|---|
HK1213927A1 (en) | 2016-07-15 |
US7875073B2 (en) | 2011-01-25 |
HK1186199A1 (en) | 2014-03-07 |
US20070073002A1 (en) | 2007-03-29 |
ES2420132T3 (en) | 2013-08-22 |
US9446173B2 (en) | 2016-09-20 |
EP2607395A1 (en) | 2013-06-26 |
EP2915829B1 (en) | 2017-10-25 |
US20150030652A1 (en) | 2015-01-29 |
US20070065480A1 (en) | 2007-03-22 |
JP2007514808A (en) | 2007-06-07 |
US7261946B2 (en) | 2007-08-28 |
EP1682593A2 (en) | 2006-07-26 |
EP2607395B1 (en) | 2015-04-01 |
EP1682593B1 (en) | 2013-04-10 |
US20050107531A1 (en) | 2005-05-19 |
EP2915829A1 (en) | 2015-09-09 |
US8883175B2 (en) | 2014-11-11 |
WO2005049678A3 (en) | 2005-09-01 |
ES2541326T3 (en) | 2015-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1682593B1 (en) | Block copolymers of acrylates and methacrylates with fluoroalkenes | |
US9289535B2 (en) | Polymers of fluorinated monomers and hydrocarbon monomers | |
EP2046848B1 (en) | Random copolymers of methacrylates and acrylates | |
US8017142B2 (en) | Polysulfone block copolymers as drug-eluting coating material | |
EP2038319B1 (en) | Block copolymers including a methoxyethyl methacrylate midblock |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006539794 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004800949 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004800949 Country of ref document: EP |